Jasper Therapeutics Initiates Strategic Alternatives Review

Jasper Therapeutics' Board of Directors has initiated a comprehensive review of strategic alternatives to maximize shareholder value. Options under consideration include a sale or licensing of assets, collaborations, a company sale, business combination, merger, or an orderly wind-down of operations. The clinical-stage biotechnology company, focused on developing briquilimab for mast cell driven diseases, will also evaluate cost-saving measures and maintain regulatory compliance during this process. There is no defined timeline, and no assurance that the process will result in any specific action or maximize stockholder value.